180 related articles for article (PubMed ID: 8109927)
1. Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.
Alcouloumre MS; Ghannoum MA; Ibrahim AS; Selsted ME; Edwards JE
Antimicrob Agents Chemother; 1993 Dec; 37(12):2628-32. PubMed ID: 8109927
[TBL] [Abstract][Full Text] [Related]
2. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
[TBL] [Abstract][Full Text] [Related]
3. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
4. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
6. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Nooney L; Matthews RC; Burnie JP
Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
[TBL] [Abstract][Full Text] [Related]
8. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD
Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergism of concentrated Allium sativum extract and amphotericin B against Cryptococcus neoformans.
Davis LE; Shen J; Royer RE
Planta Med; 1994 Dec; 60(6):546-9. PubMed ID: 7809209
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro.
Yeaman MR; Ibrahim AS; Edwards JE; Bayer AS; Ghannoum MA
Antimicrob Agents Chemother; 1993 Mar; 37(3):546-53. PubMed ID: 8460923
[TBL] [Abstract][Full Text] [Related]
12. Effects of melanin upon susceptibility of Cryptococcus to antifungals.
Ikeda R; Sugita T; Jacobson ES; Shinoda T
Microbiol Immunol; 2003; 47(4):271-7. PubMed ID: 12801064
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
14. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.
Faria NC; Kim JH; Gonçalves LA; Martins Mde L; Chan KL; Campbell BC
Lett Appl Microbiol; 2011 May; 52(5):506-13. PubMed ID: 21332761
[TBL] [Abstract][Full Text] [Related]
15. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
16. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole.
Wei GX; Bobek LA
J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.
Barchiesi F; Giacometti A; Cirioni O; Arzeni D; Silvestri C; Kamysz W; Abbruzzetti A; Riva A; Kamysz E; Scalise G
Peptides; 2007 Aug; 28(8):1509-13. PubMed ID: 17698253
[TBL] [Abstract][Full Text] [Related]
18. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
[TBL] [Abstract][Full Text] [Related]
19. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans].
Fernández Andreu CM; Pimentel Turino T; Martínez Machín G; González Miranda M
Rev Cubana Med Trop; 1999; 51(1):55-7. PubMed ID: 10887558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
